argenx (NASDAQ:ARGX) Earns Average Rating from Stifel Nicolaus

argenx (NASDAQ:ARGX)‘s stock had its “average” rating reaffirmed by analysts at Stifel Nicolaus in a note issued to investors on Thursday, January 9th, AnalystRatings.com reports.

Several other research analysts have also recently issued reports on the stock. Zacks Investment Research upgraded shares of argenx from a “hold” rating to a “buy” rating and set a $180.00 target price on the stock in a report on Thursday, January 2nd. Wells Fargo & Co initiated coverage on shares of argenx in a research report on Friday, September 27th. They issued a “market perform” rating and a $125.00 price objective for the company. Piper Jaffray Companies increased their price objective on shares of argenx from $177.00 to $194.00 and gave the company an “overweight” rating in a research report on Monday, January 6th. Credit Suisse Group initiated coverage on shares of argenx in a research report on Tuesday, November 5th. They issued a “neutral” rating and a $137.00 price objective for the company. Finally, Cowen initiated coverage on shares of argenx in a research report on Friday, September 13th. They issued a “buy” rating for the company. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and eleven have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $168.25.

argenx stock traded down $0.44 during midday trading on Thursday, hitting $151.03. 1,993 shares of the company’s stock were exchanged, compared to its average volume of 134,229. argenx has a 12 month low of $100.20 and a 12 month high of $169.50. The firm has a 50-day moving average of $156.77 and a two-hundred day moving average of $137.44. The company has a market cap of $5.85 billion, a PE ratio of -64.10 and a beta of 1.25.

A number of hedge funds have recently made changes to their positions in the business. FNY Investment Advisers LLC lifted its holdings in argenx by 21.1% in the 4th quarter. FNY Investment Advisers LLC now owns 6,631 shares of the company’s stock valued at $1,064,000 after purchasing an additional 1,156 shares in the last quarter. Gilder Gagnon Howe & Co. LLC purchased a new position in argenx in the 3rd quarter valued at $16,975,000. Millennium Management LLC lifted its holdings in argenx by 115.9% in the 3rd quarter. Millennium Management LLC now owns 115,463 shares of the company’s stock valued at $13,158,000 after purchasing an additional 61,983 shares in the last quarter. Redmile Group LLC lifted its holdings in argenx by 1.1% in the 3rd quarter. Redmile Group LLC now owns 1,080,432 shares of the company’s stock valued at $123,126,000 after purchasing an additional 11,600 shares in the last quarter. Finally, Voloridge Investment Management LLC lifted its holdings in argenx by 769.0% in the 3rd quarter. Voloridge Investment Management LLC now owns 23,619 shares of the company’s stock valued at $2,692,000 after purchasing an additional 20,901 shares in the last quarter. Institutional investors own 58.69% of the company’s stock.

argenx Company Profile

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.

Recommended Story: What sectors are represented in the FTSE 100 index?

Analyst Recommendations for argenx (NASDAQ:ARGX)

Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.